ARTICLE | Clinical News
Indacaterol/glycopyrronium bromide: Additional Phase III data
September 19, 2016 7:00 AM UTC
Additional data from the 52-week, double-blind, international Phase III FLAME trial in 3,362 patients with moderate to very severe COPD showed that once-daily 110/50 ug Ultibro Breezhaler significantl...